DUBLIN
Research and Markets (http://www.researchandmarkets.com/research/9kvfqr/ulcerative) has announced the addition of Decision Resources, Inc’s new report “Ulcerative Colitis (Event Driven)” to their offering.
Although colectomy is curative for the potentially fatal immune disease ulcerative colitis (UC), this procedure is life altering, and therefore unmet need remains for additional pharmacotherapies that more effectively treat moderate to severe disease and maintain disease remission better than do existing drugs. The increasing use of tumor necrosis factor-alpha (TNF-a) inhibitors and the uptake of two emerging therapies with a novel mechanism of action among patients with moderate to severe disease will drive strong growth of the UC market throughout our 2010-2020 forecast period, while innovative reformulations of current therapies will expand treatment options for patients with mild to moderate UC.
Key Topics Covered:
– Executive Summary
– 1 Etiology and Pathophysiology
– 2 Epidemiology and Patient Populations
– 3 Current Therapies and Medical Practice
– 4 Unmet Needs
– 5 Emerging Therapies
– 6 Market Outlook
– Appendix A BibliographyUlcerative Colitis
– Appendix B Market Forecast Methodology
– Appendix C Experts InterviewedUlcerative Colitis
– Appendix D Supplemental Epidemiology Bibliography
– Tables and Figures
For more information visit http://www.researchandmarkets.com/research/9kvfqr/ulcerative
Source: Decision Resources, Inc
CONTACT
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare
and Medical Devices, Pharmaceuticals
